Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,632 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06360471Recruiting
Preserving fertility in women with cancer
This study helps women with cancer keep their ability to have children after treatment. It offers egg or embryo freezing and checks on pregnancy and baby health later on.
Nanjing, JiangsuAges 20–40 - NCT06361043Recruiting
Adaptive radiation therapy for esophageal cancer
This study tests a new, more precise type of radiation therapy for esophageal cancer that adjusts the treatment in real time using a special CT scan. It aims to deliver a stronger dose to the tumor while sparing healthy tissue, which could improve outcomes.
BernAges 18 years+ - NCT06361316Recruiting
Liposomal irinotecan with chemo after pancreatic cancer surgery
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06361420Recruiting
Lung-protective breathing during aortic dissection repair
This study tests a special way of using a breathing machine during surgery to protect your lungs. It is for people who are having surgery to fix a tear in the main artery of the heart (acute type A aortic dissection).
Fuzhou, FujianAges 14–70 - NCT06361940RecruitingPhase 2
Short-term hormone therapy before breast cancer surgery
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06361888RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced pancreatic cancer
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Nanjing, JiangsuAges 18–75 - NCT06363773Recruiting
Using radiation to help immunotherapy work again in metastatic cancer
This study tests whether targeted radiation can help your immune system respond to immunotherapy again if your cancer has stopped responding. You would continue your current immunotherapy and receive a few focused radiation doses to one tumor site.
Soyaux, CharenteAges 18 years+ - NCT06364267RecruitingPhase 2
Low dose exemestane vs low dose tamoxifen for breast cancer prevention
This trial compares two low-dose medications, exemestane and tamoxifen, to see which is better at preventing breast cancer in postmenopausal women who have a higher risk. You would take one of these pills daily for a few years, and the study will check how well it works and what side effects occur.
Genova, ItalyAges Any age - NCT06364631RecruitingPhase 3
Testing a new approach for advanced kidney cancer
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
ViennaAges 18 years+ - NCT06368141RecruitingPhase 2
Chemo plus immunotherapy before surgery for colon cancer
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06375473Recruiting
Study of irinotecan liposome for pancreatic cancer
This study looks at how well a specific type of chemotherapy called irinotecan hydrochloride liposome works in people with pancreatic cancer. Researchers want to understand its effects in real-world settings, which may help doctors choose the best treatment for patients.
Hefei, AnhuiAges 18–100 - NCT06380101Recruiting
Special diet with standard therapy for rectal cancer
This trial tests a special medical food that limits certain amino acids (building blocks of protein) during standard treatment for rectal cancer. The goal is to see if this diet helps the treatment work better while reducing side effects.
Tampa, FloridaAges 18–100 - NCT06384053Recruiting
Heat plus radiation for skin cancer in older adults
This trial tests whether adding heat therapy (hyperthermia) to radiation therapy works well for older adults with larger non-melanoma skin cancers. It may help shrink tumors without needing surgery.
Aarau, Canton of AargauAges 65 years+ - NCT06383767RecruitingPhase 3
A study of ESG401 for advanced HR+/HER2- breast cancer
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06384924Recruiting
Testing a light-based tool for skin cancer detection
This trial is testing a special light-based technique (Raman spectroscopy) to see if it can help doctors better identify skin cancers. It is for people with either basal cell or squamous cell carcinoma who are scheduled to receive brachytherapy treatment.
Stony Brook, New YorkAges 18 years+ - NCT06385418RecruitingPhase 2
Colon chemotherapy for colorectal cancer
This trial tests putting a chemo drug (fluorouracil) directly into the colon through a tube. It's for people with colorectal cancer who are already getting other cancer treatment, to see if adding local chemo helps shrink the main tumor.
Nanjing, JiangsuAges 18–75 - NCT06385717Recruiting
ESD plus chemoradiotherapy for early esophageal cancer
This study tests whether combining radiation and chemotherapy after endoscopic removal of early-stage esophageal cancer can effectively treat the cancer without needing surgery. It may be an option for people whose cancer was removed with ESD but who want to avoid additional surgery.
Hangzhou, ZhejiangAges 18–75 - NCT06386107Recruiting
Bleeding risk in people with cancer and blood clots on blood thinners
This study looks at how well blood thinners work in people with cancer and a recent blood clot. It measures the risk of bleeding by checking certain blood clotting factors.
Clermont-FerrandAges 18 years+ - NCT06387342RecruitingPhase 2
Namodenoson for advanced pancreatic cancer
This trial tests an oral drug called Namodenoson for people with advanced pancreatic cancer that has not responded to previous treatments. The goal is to see if the drug can help slow the cancer's growth or improve symptoms.
Petah TikvaAges 18 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06388720RecruitingPhase 2
Two chemotherapy drugs for bladder cancer after BCG
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Goyang-siAges 20 years+ - NCT06389006RecruitingPhase 2
Combination therapy before surgery for HER2-low, hormone-positive breast cancer
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Fudan University Shanghai Cancer CenterAges 18 years+ - NCT06389760RecruitingPhase 2
Nimotuzumab combo after pancreatic cancer surgery
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Nanjing, JiangsuAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,632 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.